Patents by Inventor Charlotte KOPITZ

Charlotte KOPITZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-mesothelin immunoconjugates and uses therefor
    Patent number: 10647779
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: May 12, 2020
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Kopitz, Joachim Schuhmacher
  • ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20170327589
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Application
    Filed: July 21, 2017
    Publication date: November 16, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER
  • ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20150322160
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.
    Type: Application
    Filed: July 20, 2015
    Publication date: November 12, 2015
    Inventors: Antje KAHNERT, Kerstin BERHÖRSTER, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER